What theravia does

Theravia is an international pharmaceutical laboratory headquartered in Neuilly-sur-Seine, France, specializing in rare and neglected diseases. Formed in 2023 through the merger of Addmedica and CTRS, the company operates as part of the Norgine Group of Companies and serves patients with conditions including Sickle Cell Disease, Primary Bile Acid Synthesis Disorders, Multiple Myeloma, Epidermolysis Bullosa, and wound healing applications. With approximately 50 employees, Theravia markets six registered products across hematology (Siklos), hepatology (Orphacol), oncology (Neofordex, Dexliq), and wound care (Liquiband), holding Marketing Authorization Holder status for four products and distribution rights for two. The company has treated 15,000+ patients across 35+ countries spanning five continents.

Theravia's product portfolio is anchored by EMA-approved orphan and specialty drugs distributed through regulated pharmaceutical channels and regional commercial partners. The company maintains an active R&D pipeline including Ther07 (Phase 3, fertility), Ther08 (Phase 1, allergy), and A001 (preclinical, epidermolysis bullosa) — the latter based on a recombinant fusion protein (DecoDerma) licensed from Tampere University, which has received Orphan Drug and Rare Pediatric Disease Designations from both the FDA and EMA. Theravia's technology foundation includes proprietary recombinant fusion protein development supported by academic collaborations, with pipeline assets funded partly by grants (e.g., Business Finland's 2021-2023 DecoDerma funding).

Theravia generates revenue through pharmaceutical product sales, in-licensing and out-licensing arrangements, and Marketing Authorization Holder operations. The company employs a hybrid go-to-market model combining direct healthcare professional engagement (medical information, pharmacovigilance) with channel partnerships across 35+ countries. It holds HAS certification for pharmaceutical information activities in France (since March 2024) and maintains dedicated partnering infrastructure for commercial distribution, in-licensing, and out-licensing. The customer base comprises healthcare professionals, institutions, and ultimately rare disease patients, with no public revenue disclosure available.

Name

theravia

Legal name

THERAVIA SAS

Website

https://theravia.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

101–250 employees

Short description

Theravia is a French pharmaceutical laboratory specializing in rare and neglected diseases, marketing six registered products across hematology, hepatology, oncology, and wound care to 15,000+ patients in 35+ countries. Formed via the Addmedica-CTRS merger, it is part of the Norgine Group.

Ownership category

akta.pro rank

Product category

Rare Disease Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Rare Gastroenterology & Hepatology Disorder Therapies (HLAIAIAL)

Keywords

• Rare disease pharmaceuticals
• Orphan drug development
• Specialty pharma distribution
• Prescription therapeutics
• Pharmaceutical licensing

Headquarters

HQ city

Neuilly-sur-seine

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of registered pharmaceutical products across multiple therapeutic areas including hematology (Siklos), hepatology (Orphacol), oncology (Neofordex, Dexliq), and wound care (Liquiband). Products are sold through direct commercial partnerships and distribution networks in 35+ countries.
2. Licensing and Distribution Agreements: Revenue generated through in-licensing and out-licensing arrangements with academic institutions and commercial partners. Theravia in-licenses drug candidates for development and commercialization, while out-licensing products for distribution in specific territories.
3. Marketing Authorization Holder (MAH) Operations: As MAH for 4 products, Theravia holds regulatory approvals and commercializes pharmaceutical products, managing the full lifecycle from manufacturing authorization to market distribution.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Theravia is an international pharmaceutical laboratory that develops, registers, and commercializes prescription medicines for rare and neglected diseases. The company currently markets six registered products across hematology (Siklos for sickle cell disease), hepatology (Orphacol for primary bile acid synthesis disorders), oncology (Neofordex and Dexliq for multiple myeloma), and wound care (Liquiband adhesives), and holds marketing authorization for four of these. It also maintains an active R&D pipeline targeting fertility, allergy, and epidermolysis bullosa.

Product overview

Theravia is an international pharmaceutical laboratory specializing in rare and neglected diseases, formed through the merger of Addmedica and CTRS. The company currently markets six registered products: Orphacol (hepatology), Siklos (hematology), Neofordex (oncology), Dexliq (oncology), and Liquiband (wound healing). Four products are marketed as Marketing Authorization Holder (MAH) while two are distributed. The company also maintains an active R&D pipeline including Ther07 (Phase 3, fertility), Ther08 (Phase 1, allergy), and A001 (preclinical, epidermolysis bullosa). Theravia operates in more than 35 countries across 5 continents and has partnerships with leading research groups worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Orphacol: Product for hepatology therapeutic area
• Siklos
• Neofordex
• Dexliq
• Liquiband

Products and services

• Orphacol Bile acid replacement therapy for treating primary bile acid synthesis disorders, available in 50 mg and 250 mg formulations for hepatology patients with rare inherited bile acid synthesis defects.
• Siklos Hematology medication for sickle cell disease management, available in 100 mg and 1000 mg formulations, prescribed by hematologists for patients with this rare inherited blood disorder.
• Neofordex Oncology medication, a 40 mg dexamethasone formulation used in the treatment of multiple myeloma, prescribed by oncologists.
• Dexliq Oncology and other conditions medication at 4 mg/mL dexamethasone concentration, used in oncology and additional therapeutic areas.
• Liquiband Range of skin adhesives and surgical sealants for wound care and wound healing, including variants Liquiband Exceed XS, Exceed, Optima 35, Optima 50, Surgical S Clear, and Surgical S; distributed by Theravia through dedicated distributor networks.

Quantifiable outcome

• 15,000+ patients treated worldwide with life-saving medications
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Tampere UniversitycoreStrategic or Co-development PartnerTampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB) to Theravia. The licensing agreement includes extensive collaboration for development, registration, and commercialization. Theravia is responsible for further drug development and conducting clinical trials. The molecule is a recombinant fusion protein that received Orphan Drug (ODD) and Rare Pediatric Disease designations (RPDD) from both FDA and EMA. Pre-clinical studies have shown superior effectiveness compared to any previously tested molecule for this rare skin disorder. The project was funded by Business Finland from 2021 to 2023.
• Norgine GroupflagshipOthersTheravia is Part of the Norgine Group of Companies, providing corporate affiliation and likely operational support, regulatory expertise, and distribution capabilities within the specialty pharmaceutical sector.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharma company with a portfolio focused on rare neurological and hematology/oncology indications, combining in-licensed assets, MAH positioning, and global commercial infrastructure — closely matching Theravia's specialty/rare disease commercial model.
• Ultragenyx Pharmaceutical: Ultragenyx is a clinical-stage biopharmaceutical company developing and commercializing therapies for rare and ultra-rare genetic diseases, with multiple late-stage assets — comparable to Theravia's mix of commercialized rare-disease products plus active pipeline.
• Swedish Orphan Biovitrum (Sobi): Sobi is a Europe-headquartered, orphan/specialty pharmaceutical company focused on rare diseases across hematology, immunology, and specialty care — making it a close functional and strategic comparable to Theravia, especially in the rare hematology and orphan-disease positioning.
• BioMarin Pharmaceutical: BioMarin is a global rare-disease biopharmaceutical company marketing multiple enzyme-replacement and gene therapies for ultra-rare conditions — directly comparable to Theravia in rare-disease commercial focus, orphan-drug strategy, and multi-product portfolio.
• Recordati Rare Diseases: Recordati operates a dedicated rare disease business unit (Recordati Rare Diseases) marketing specialty products across multiple therapeutic areas via a partner/distribution model globally — very comparable in size, GTM, and therapeutic-area breadth to Theravia.

Regional players

• Pierre Fabre: Pierre Fabre is a French specialty pharmaceutical company with operations spanning oncology, dermatology, and rare diseases — directly comparable to Theravia as a France-based specialty pharma, though operating with a broader oncology/dermatology portfolio.

Broad incumbents

• Genzyme (Sanofi Rare Disease): Sanofi's Genzyme rare-disease franchise is a pioneer in rare-disease specialty pharmaceuticals with multiple commercial products and a global MAH infrastructure — comparable to Theravia as a broader incumbent operating in similar orphan-disease therapeutic categories.
• Alexion (AstraZeneca Rare Disease): Alexion, acquired by AstraZeneca, is a leading global rare-disease franchise (complement-mediated diseases, hematology, neurology) — comparable as a large rare-disease incumbent operating in overlapping therapeutic categories with Theravia's marketed products.
• Takeda (Shire Rare Disease): Takeda's rare-disease and plasma-derived therapies franchise, expanded through the Shire acquisition, is a global rare-disease incumbent with comparable portfolio breadth and late-stage pipeline — relevant as a peer for both therapeutic-area and licensing/expansion strategy.
• Ipsen: Ipsen is a European-headquartered specialty pharmaceutical company focused on rare diseases, oncology, and neuroscience — comparable in scale, European regulatory center-of-gravity, and specialty-pharma operating model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/theraviapharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about theravia